Navigation Links
Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
Date:1/8/2009

KING OF PRUSSIA, Pa., Jan. 8 /PRNewswire/ -- Prism Pharmaceuticals announced today that it will receive a $10 million milestone payment from Paul Capital Healthcare (formerly Paul Royalty Funds), the healthcare investment platform of Paul Capital. The milestone payment is triggered by the recent U.S. Food and Drug Administration (FDA) approval of Prism's new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV. The long range financing agreement with Paul Capital Healthcare, established in September 2006, provides Prism with non-dilutive capital to bring NEXTERONE through to commercial launch in the US.

The September 2006 financing secured up to $68 million in capital from Paul Capital Healthcare and Essex Woodlands Health Ventures Fund VI, through a combination of equity and a revenue interest financing, which is funded based on the satisfaction of certain predetermined milestones.

"The flexible, forward-looking provisions of the Revenue Interest Assignment Agreement structured between Prism and Paul Capital are demonstrating its true value in the current financing climate surrounding emerging biopharmaceutical companies," said Dr. Warren D. Cooper, President and CEO of Prism Pharmaceuticals. "Our financial circumstances and ongoing support enable us to remain wholly focused on execution of our business plan and leveraging the NDA approval of our first product."

"Our initial investment in Prism Pharmaceuticals was based on the great potential of the company's approach to an alternative formulation of amiodarone and other drugs, and our belief in management's ability to bring new products to the market," said Dr. Walter Flamenbaum, a partner at Paul Capital Healthcare. "The capital provided by our Revenue Interest Assignment Agreement - a form of "synthetic royalty" agreement - with
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
3. Prism glasses expand the view for patients with hemianopia
4. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
5. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
6. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
7. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
8. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
9. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
10. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... did the earliest birds take wing? Did they fall from ... Or did they run along the ground and pump their ... million years in the past, but a new University of ... birds have an innate ability to maneuver in midair, a ... rather than fall from a perch. , The study looked ...
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... A herbal preparation prescribed by a Chinese herbal ... in life-threatening heart changes, prompting a team of ... appropriate patient education by practitioners who prescribe complementary ... , the journal of the Australasian College for ... and Dr Nicky Dobos from the Intensive Care ...
Breaking Medicine News(10 mins):Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2
... Bulgaria’s Agriculture Minister Nihat Kabil has revealed that ... bird flu. The bird was however not infected ... dangerous H5 virus. The dead swan was found ... was unable to say whether avian flu had ...
... expected in poultry during the course of 2006, according to ... take place // among human beings on a large scale, ... Governments have however been called upon to be prepared ... have been called upon to improve their surveillance where the ...
... end up losing as many as over 200 doctors, over the ... abortion. // The Catholic doctors who are from Queensland are of ... be deprived of his powers when it comes to deciding upon ... ,The AMA on the other hand is calling for ...
... meeting with Boston Scientific to talk about the repairs in ... held in 2001 with Schering-Plough // about problems with its ... to make any amendments. This provoked the FDA to withhold ... solve this problem Raul E. Cesan, the company's president and ...
... of the Teratology Society published a paper in the journal ... ,In this paper they said that overweight and ... develop medical problems at birth. ,This paper talked ... obese mothers. , It is stated that they ...
... closely monitored surveillance for patients with colon and rectal ... recurrence // compared to less aggressive strategy which is ... found that an intensified follow up of patients in ... diagnosis of cancer recurrence which could help in treatment ...
Cached Medicine News:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... , August 28, 2014 ... "DNA diagnostics Market (products, applications, techniques, end users ... Growth and Forecast, 2013 - 2020," indicates that ... billion by 2020 registering a CAGR of 9.8% ... accurate diagnosis and cost effectiveness over alternative diagnostic ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc. ... focused on obtaining FDA clearance for and commercializing its ... test for aiding in identifying children, adolescent, and young ... low risk for appendicitis, today announced it will present ... 16 th Annual Global Investment Conference being held ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
For the quantitative determination of alkaline phosphatase in human serum....
... of low density lipoprotein cholesterol ... Liquid stable, ready-to-use reagent. Selective ... measurement. Excellent correlation with established ... substances. Available with Calibrator: Trucal ...
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: